A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Hatem SolimanBrian Czerniecki

Abstract

Talimogene laherparepvec (TVEC) is an oncolytic herpes simplex 1 virus approved for treatment of melanoma. We hypothesized intratumoral TVEC may enhance response to neoadjuvant chemotherapy (NAC). This article reports the results of a trial combining NAC with TVEC for triple-negative breast cancer (TNBC). Patients with stage II-III TNBC enrolled in a 3+3 phase I trial (NCT02779855) of two TVEC dose levels [DL; DL 1 = 106 plaque-forming units (PFU) × 5 doses; DL 2 = 106 PFUs first dose, then 108 PFUs × 4 doses] on weeks 1, 4, 6, 8, and 10 plus weekly paclitaxel (80 mg/m2) for 12 weeks, followed by doxorubicin/cyclophosphamide (60/600 mg/m2) every 2 weeks for 8 weeks. Postoperative response assessment using residual cancer burden (RCB) was performed. Primary endpoints were safety and MTD. Secondary endpoints were RCB0 rate and immune correlates. Dose-limiting toxicity (DLT) rule was grade 3-5 adverse events due to TVEC during first 5 weeks. Nine patients [DL 1 (n = 3); DL 2 (n = 6)] were enrolled. Six had stage II disease, and 3 had stage III (6 clinically N+). No DLTs occurred, and MTD was DL 2. Most common toxicities with TVEC were fever (n = 8), chills (n = 3), hematomas (n = 3), and injection site pain (n = 3). Thromboembolic...Continue Reading

References

Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jun 28, 2014·Journal for Immunotherapy of Cancer·Howard L KaufmanCraig L Slingluff
Nov 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George T BuddGabriel N Hortobagyi
Jun 17, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph A SparanoNancy E Davidson
Jul 17, 2015·JAMA Oncology·Donald A Berry, Clifford A Hudis
Nov 3, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Barbara Ingold HeppnerSibylle Loibl
Feb 27, 2020·The New England Journal of Medicine·Peter SchmidUNKNOWN KEYNOTE-522 Investigators

❮ Previous
Next ❯

Citations

Oct 9, 2021·Breast Cancer Research and Treatment·Alberto Hernando-CalvoPhilippe L Bedard
Oct 31, 2021·Breast Cancer Research and Treatment·Laura A HuppertHatem H Soliman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.